FilingsTodayInsmed
At a glance
Insmed reported 2025 revenue of $606.4M, up 66.7% from $363.7M in 2024. Over 4 years since 2021 ($188.5M), that is growth of about 33.9% a year. Operating margin was -205.6%, down from -199% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2021, 2022, 2023, 2024 and 2025.
In the last 12 months 10 insiders reported 0 open-market purchases and 59 sales ($167.1M). 35 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $32M by Chief Operating Officer Roger Adsett on Aug 12, 2026.
Insmed filed 13 current reports (Form 8-K) in the last 12 months, most often for regulation fd disclosure (6), results of operations (4), other events (4) and officer or director change (3). The latest officer or director change was reported on Oct 20, 2026.
3 of the 20 investors tracked here held Insmed at the last quarter end, worth $51.6M combined. It is the largest weight for Duquesne Family Office (3.5% of its portfolio), followed by Bridgewater Associates (0.2%). Added: Duquesne Family Office and Bridgewater Associates. Reduced: National Pension Service (Korea).
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | -$434.7M | -$481.5M | -$749.6M | -$913.8M | -$1.28B |
| Diluted EPS | $-3.88 | $-3.91 | $-5.34 | $-5.57 | $-6.42 |
Fiscal year ends Dec 31 · incorporated in VA
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined